--- title: "43% smaller, sense-capable: China's new brain pacemaker and the closed-loop gap" date: 2026-11-04 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-closed-loop-dbs-parkinson language: en --- # 43% smaller, sense-capable: China's new brain pacemaker and the closed-loop gap > PINS Medical's (品驰医疗) G108R 'super brain pacemaker' can record brain signals while it stimulates — a prerequisite for closed-loop DBS, which remains investigational for Parkinson's. For three decades, the brain pacemaker has been a one-way device. It sends electricity into the brain and hopes for the best, firing the same pattern whether the patient is resting, walking, or mid-tremor. A new Chinese implant is trying to change that — by listening at the same time it talks. In early 2026, Beijing PINS Medical (品驰医疗) won regulatory approval for the G108R, a next-generation deep brain stimulation (DBS, 脑深部电刺激) system the company calls its "super brain pacemaker (超级脑起搏器)." Its headline features are not just smaller hardware but a bidirectional trick: it stimulates while simultaneously recording the brain's own electrical activity. That is the foundational capability a truly closed-loop system would need — one that adjusts stimulation in real time to what the brain is actually doing. ## Key takeaways - China's established DBS therapy for Parkinson's is **open-loop directional stimulation**, with PINS's directional system approved by the NMPA in May 2024. - The 2026 **G108R** adds on-device signal sensing and decoding, marketed as a step toward **closed-loop (adaptive) DBS**. - True adaptive closed-loop — where stimulation responds automatically to neural biomarkers — is **still investigational**, not yet a standard approved therapy in China. - SceneRay (景昱医疗) pursues a different differentiator: **dual-target (双靶点)** stimulation, with Parkinson's as its long-standing approved indication. ## What "closed-loop" actually means Open-loop DBS is a scheduled pulse. Surgeons implant leads into a deep nucleus — typically the subthalamic nucleus (底丘脑核, STN) or the globus pallidus interna (内侧苍白球, GPi) — and a pulse generator underneath the collarbone delivers continuous electrical stimulation tuned during clinic visits. It works well for many Parkinson's patients, smoothing tremor and rigidity, but the settings are static between appointments. Closed-loop, or adaptive, DBS changes that. The device reads a neural biomarker — most famously the elevated beta-band oscillations that rise when Parkinsonian symptoms worsen — and dials stimulation up or down accordingly. The theoretical payoff is better symptom control with less battery drain and fewer side effects from over-stimulation. Globally, adaptive DBS has shown promise in trials but has not become the routine standard of care. ## What China has actually approved The regulatory reality is more modest than the marketing language suggests. In May 2024, China's NMPA approved PINS's directional DBS products — the first domestically developed directional systems — which can target specific sub-regions of a nucleus with extra contacts, reducing side effects when leads are slightly misplaced. The approval covers advanced Parkinson's disease with levodopa-induced dyskinesia, where medication alone no longer controls symptoms. The 2026 G108R builds on that. According to PINS, it is 43 percent smaller than its predecessor, recharges in roughly 20–30 minutes per week via medical-grade fast charging, and — critically — can record deep-brain signals while stimulating. The company describes future upgradability to closed-loop function, implying the adaptive algorithm is not yet the shipped default mode. That distinction matters: a sense-capable implant is necessary but not sufficient for approved adaptive therapy. China is, however, building the measurement rules. A national industry standard, YY/T 1996-2025, titled *Test method for perception and response performance of closed-loop implantable neurostimulators*, was published in 2025 — a signal that regulators expect closed-loop devices to arrive and want a common yardstick to judge them. ## The dual-target alternative While PINS pushes bidirectional sensing, SceneRay (景昱医疗) of Suzhou has staked out another frontier: dual-target (双靶点) DBS. Rather than stimulating a single nucleus, its system aims at two structures at once — for example the nucleus accumbens and the anterior limb of the internal capsule — a design the company originally developed for addiction and obsessive-compulsive indications. For Parkinson's, dual targeting is positioned as a way to cover a broader symptom network. SceneRay received U.S. FDA Breakthrough Device designation for its addiction DBS and, in December 2025, secured China's NMPA approval for an implantable deep-brain neurostimulation system indicated for drug addiction — described as the world's first invasive-BCI product approved for an addiction psychiatric indication. Parkinson's remains the company's established, longer-standing therapeutic area. The point for readers: "DBS innovation" is not one race but several — directional precision, bidirectional sensing, and multi-target coverage are three different bets. ## Policy tailwind, with guardrails BCI was named a future-industry priority in China's 2026 government work report, and a July 2025 implementing opinion from seven ministries (led by MIIT) set a 2027 target for key technological breakthroughs. But the same documents stress clinical rigor and ethics review. For a therapy as intimate as brain stimulation, the gap between a capable implant and an approved adaptive therapy is filled with trials, not press releases. ## What readers can do now - **Parkinson's patients considering DBS should understand the mode they are being offered** — current approved therapy in China is overwhelmingly open-loop or directional, not adaptive closed-loop. - **Ask clinicians whether the device is sense-capable and whether closed-loop is active or future-planned**, since marketing terms blur the two. - **Track the YY/T 1996-2025 standard** as the benchmark: when a closed-loop DBS claims approval, ask which perceptual and response tests it passed. ## Honest limitations This piece draws on PINS's official product pages and milestone announcements, the NMPA's English approval notice for the 2024 directional DBS, and trade/forum coverage of the 2026 Zhongguancun Forum. Company-stated figures — 43 percent size reduction, 20–30 minute weekly charging, and the "future closed-loop" characterization — are reported as the company presents them and were not independently verified by me. The precise regulatory status of *adaptive* closed-loop DBS in China (approved vs. trial-only) is genuinely ambiguous in public sources; I have therefore described sense-capable hardware as approved and fully adaptive therapy as investigational, which is the conservative reading. SceneRay's December 2025 NMPA approval is for addiction, not Parkinson's; I have kept the Parkinson's reference to its established indication only. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-closed-loop-dbs-parkinson Free to quote with attribution and a link to the original.